1. Home
  2. EXAS vs GRAB Comparison

EXAS vs GRAB Comparison

Compare EXAS & GRAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

N/A

Current Price

$103.31

Market Cap

19.7B

Sector

Health Care

ML Signal

N/A

Logo Grab Holdings Limited

GRAB

Grab Holdings Limited

N/A

Current Price

$3.77

Market Cap

16.5B

ML Signal

N/A

Company Overview

Basic Information
Metric
EXAS
GRAB
Founded
1995
2012
Country
United States
Singapore
Employees
N/A
11267
Industry
Medical Specialities
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
19.7B
16.5B
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
EXAS
GRAB
Price
$103.31
$3.77
Analyst Decision
Hold
Strong Buy
Analyst Count
17
4
Target Price
$86.62
$6.38
AVG Volume (30 Days)
1.8M
35.3M
Earning Date
05-07-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
80.32
N/A
EPS
N/A
N/A
Revenue
$4,144,000.00
N/A
Revenue This Year
$15.37
$23.20
Revenue Next Year
$12.41
$20.23
P/E Ratio
N/A
$74.17
Revenue Growth
N/A
N/A
52 Week Low
$38.88
$3.36
52 Week High
$104.02
$6.62

Technical Indicators

Market Signals
Indicator
EXAS
GRAB
Relative Strength Index (RSI) 54.45 30.50
Support Level $102.95 N/A
Resistance Level $103.77 $5.25
Average True Range (ATR) 0.31 0.14
MACD -0.09 -0.02
Stochastic Oscillator 33.18 2.36

Price Performance

Historical Comparison
EXAS
GRAB

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

About GRAB Grab Holdings Limited

Founded in 2012, Grab provides ride-sharing services, food and grocery delivery, and financial services (payments, consumer loans, and enterprise offerings) in eight Southeast-Asian countries through its mobile platform. The company partners with merchants and riders, connecting them with consumers while charging commission to both sides. Grab has a leading market share in and derives 89% of its revenue from its core businesses, ride-sharing and food delivery. Singapore, Indonesia, and Malaysia contributed more than 70% of revenue in 2024. Grab's main competitors in Southeast Asia are Line Man and Goto. Its financial services business is still in its nascent stage and provides minimal revenue currently. The company now also generates advertising revenue.

Share on Social Networks: